WO2007084391A3 - Thiazole compounds as protein kinase b ( pkb) inhibitors - Google Patents

Thiazole compounds as protein kinase b ( pkb) inhibitors Download PDF

Info

Publication number
WO2007084391A3
WO2007084391A3 PCT/US2007/000871 US2007000871W WO2007084391A3 WO 2007084391 A3 WO2007084391 A3 WO 2007084391A3 US 2007000871 W US2007000871 W US 2007000871W WO 2007084391 A3 WO2007084391 A3 WO 2007084391A3
Authority
WO
WIPO (PCT)
Prior art keywords
thiazole compounds
pkb
protein kinase
inhibitors
compositions
Prior art date
Application number
PCT/US2007/000871
Other languages
French (fr)
Other versions
WO2007084391A2 (en
Inventor
Qingping Zeng
John G Allen
Matthew P Bourbeau
Celia Dominguez
Christopher H Fotsch
Nianhe Han
Fang-Tsao Hong
Xin Huang
Matthew R Lee
Aiwen Li
Qingyian Liu
James T Rider
Seifu Tadesse
Andrew S Tasker
Vellarkad N Viswanadhan
Xianghong Wang
Kurt E Weiler
George E Wohlhieter
Guomin Yao
Chester Chenguang Yuan
Original Assignee
Amgen Inc
Qingping Zeng
John G Allen
Matthew P Bourbeau
Celia Dominguez
Christopher H Fotsch
Nianhe Han
Fang-Tsao Hong
Xin Huang
Matthew R Lee
Aiwen Li
Qingyian Liu
James T Rider
Seifu Tadesse
Andrew S Tasker
Vellarkad N Viswanadhan
Xianghong Wang
Kurt E Weiler
George E Wohlhieter
Guomin Yao
Chester Chenguang Yuan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Qingping Zeng, John G Allen, Matthew P Bourbeau, Celia Dominguez, Christopher H Fotsch, Nianhe Han, Fang-Tsao Hong, Xin Huang, Matthew R Lee, Aiwen Li, Qingyian Liu, James T Rider, Seifu Tadesse, Andrew S Tasker, Vellarkad N Viswanadhan, Xianghong Wang, Kurt E Weiler, George E Wohlhieter, Guomin Yao, Chester Chenguang Yuan filed Critical Amgen Inc
Priority to BRPI0706621-0A priority Critical patent/BRPI0706621A2/en
Priority to JP2008551297A priority patent/JP5199885B2/en
Priority to EA200801716A priority patent/EA200801716A1/en
Priority to CA2636077A priority patent/CA2636077C/en
Priority to ES07718125T priority patent/ES2389062T3/en
Priority to EP07718125A priority patent/EP1981884B1/en
Priority to AU2007207743A priority patent/AU2007207743B2/en
Publication of WO2007084391A2 publication Critical patent/WO2007084391A2/en
Publication of WO2007084391A3 publication Critical patent/WO2007084391A3/en
Priority to IL192751A priority patent/IL192751A0/en
Priority to NO20083572A priority patent/NO20083572L/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Abstract

The invention relates to thiazole compounds of Formula (I) and Formula (II) and compositions thereof useful for treating diseases mediated by protein kinase B (PKB) where the variables have the definitions provided herein. The invention also relates to the therapeutic use of such thiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.
PCT/US2007/000871 2006-01-18 2007-01-11 Thiazole compounds as protein kinase b ( pkb) inhibitors WO2007084391A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0706621-0A BRPI0706621A2 (en) 2006-01-18 2007-01-11 compound, pharmaceutical composition, methods for treating a kinase-mediated disorder in a mammal and for treating a proliferation-related disorder in a mammal, and, use of the compound
JP2008551297A JP5199885B2 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase B (PKB) inhibitors
EA200801716A EA200801716A1 (en) 2006-01-18 2007-01-11 THIAZOLE COMPOUNDS AND THEIR APPLICATION
CA2636077A CA2636077C (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase b (pkb) inhibitors
ES07718125T ES2389062T3 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase B inhibitors (PKB)
EP07718125A EP1981884B1 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase b (pkb) inhibitors
AU2007207743A AU2007207743B2 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase B (PKB) inhibitors
IL192751A IL192751A0 (en) 2006-01-18 2008-07-10 Thiazole compounds as protein kinase b (pkb) inhibitors
NO20083572A NO20083572L (en) 2006-01-18 2008-08-18 Thiazole compounds as protein kinase-B (PKB) inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18
US60/759,546 2006-01-18

Publications (2)

Publication Number Publication Date
WO2007084391A2 WO2007084391A2 (en) 2007-07-26
WO2007084391A3 true WO2007084391A3 (en) 2008-03-20

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000871 WO2007084391A2 (en) 2006-01-18 2007-01-11 Thiazole compounds as protein kinase b ( pkb) inhibitors

Country Status (21)

Country Link
US (2) US7514566B2 (en)
EP (1) EP1981884B1 (en)
JP (1) JP5199885B2 (en)
KR (1) KR20080091369A (en)
CN (1) CN101421265A (en)
AR (1) AR059064A1 (en)
AU (1) AU2007207743B2 (en)
BR (1) BRPI0706621A2 (en)
CA (1) CA2636077C (en)
CR (1) CR10211A (en)
EA (1) EA200801716A1 (en)
ES (1) ES2389062T3 (en)
IL (1) IL192751A0 (en)
MY (1) MY149143A (en)
NO (1) NO20083572L (en)
PE (1) PE20071114A1 (en)
TW (1) TW200738657A (en)
UA (1) UA91895C2 (en)
UY (1) UY30098A1 (en)
WO (1) WO2007084391A2 (en)
ZA (1) ZA200806386B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA012181B1 (en) 2004-10-18 2009-08-28 Амген, Инк. Thiadiazole compounds and use thereof
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
JP2010518159A (en) * 2007-02-13 2010-05-27 シェーリング コーポレイション Function-selective α2C adrenergic receptor agonist
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2009158372A1 (en) * 2008-06-26 2009-12-30 Smithkline Beecham Corporation Inhibitors of akt activity
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CN102186833A (en) * 2008-08-18 2011-09-14 耶鲁大学 MIF modulators
LT2356109T (en) * 2008-10-10 2017-03-27 Vm Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
US8232273B2 (en) * 2008-12-19 2012-07-31 Genentech, Inc. Heterocyclic compounds and methods of use
EP2387570A1 (en) * 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
DK2445502T4 (en) 2009-06-25 2022-11-28 Alkermes Pharma Ireland Ltd HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS
ES2532026T3 (en) * 2009-10-08 2015-03-23 Glaxosmithkline Llc Combination
EA023018B1 (en) * 2009-10-08 2016-04-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Combination for treating cancer and/or pre-cancerous syndromes
BR112012008519A2 (en) * 2009-10-12 2016-04-05 Glaxosmithkline Llc combination
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EA027123B1 (en) 2009-11-05 2017-06-30 Ризен Фармасьютикалз С.А. Pi3k kinase inhibitors
WO2011115071A1 (en) * 2010-03-15 2011-09-22 国立大学法人広島大学 Thienopyridine derivative, method for producing same and organic semiconductor device using same
JP5578705B2 (en) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 (Aryl) difluoroacetic acid ester derivative and method for producing the same
CN102933571A (en) * 2010-04-16 2013-02-13 Abbvie公司 Phthalazin-(2h)-one inhibitors of kinases
EP2579872A4 (en) * 2010-04-23 2013-11-13 Merck Sharp & Dohme Inhibitors of akt activity
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
JO2998B1 (en) 2010-06-04 2016-09-05 Amgen Inc Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
AU2012250576B2 (en) 2011-05-04 2017-04-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinases
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
CN103304468A (en) * 2012-03-13 2013-09-18 华东师范大学 One-pot series synthetic method of oxoindole
EP2832731A4 (en) * 2012-03-27 2015-08-19 Shionogi & Co Aromatic heterocyclic five-membered ring derivative having trpv4 inhibitory activity
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
EP2870157B1 (en) 2012-07-04 2017-08-30 Rhizen Pharmaceuticals S.A. Selective pi3k delta inhibitors
US20160002185A1 (en) 2013-02-19 2016-01-07 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
BR112015022431A2 (en) * 2013-03-13 2017-05-09 Boston Biomedical Inc 3- (aryl or heteroaryl) methyleneindolin-2-one derivatives as cancer stem cell signaling pathway kinase inhibitors for cancer treatment
AU2014236812B2 (en) 2013-03-14 2018-03-01 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (en) 2013-06-10 2017-06-16 Amgen Inc Processes of Making and Crystalline Forms of a MDM2 Inhibitor
EP3068393B9 (en) 2013-11-11 2022-07-20 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
KR20170122799A (en) * 2015-03-02 2017-11-06 리겔 파마슈티칼스, 인크. TGF-beta Inhibitor
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
EP3426652B1 (en) * 2016-03-10 2021-12-01 Astrazeneca AB Novel inhibitors of phosphatidylinositol 3-kinase gamma
AU2018243770A1 (en) 2017-03-30 2019-09-19 F. Hoffmann-La Roche Ag Isoquinolines as inhibitors of HPK1
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
DK3691620T3 (en) 2017-10-05 2022-10-03 Fulcrum Therapeutics Inc P38 KINASE INHIBITOR REDUCES DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
JP7266043B2 (en) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド KRas G12C inhibitors and methods of using them
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
AU2020280024A1 (en) 2019-05-21 2021-12-09 Amgen Inc. Solid state forms
AU2020325115A1 (en) * 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
CN111603466B (en) * 2020-06-29 2022-07-22 江南大学 Application of ethanone compound in preparation of tumor treatment drug
CN114014787B (en) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 Asymmetric synthesis method for preparing (2S,3R) -p-methylsulfonylphenylserine ethyl ester
CN116813608A (en) * 2023-06-08 2023-09-29 英矽智能科技(上海)有限公司 Thiazole compound and application thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US20010044545A1 (en) * 2000-04-03 2001-11-22 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US20030078252A1 (en) * 2001-05-11 2003-04-24 Pfizer Inc. Thiazole derivatives
US20040122016A1 (en) * 2002-10-30 2004-06-24 Jingrong Cao Compositions useful as inhibitors of rock and other protein kinases
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006044860A2 (en) * 2004-10-18 2006-04-27 Amgen, Inc. Thiadiazole compounds and methods of use

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (en) 1973-11-08 1977-10-07
US4086239A (en) 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (en) 1978-06-02 1987-06-29 Pfizer METHOD OF ANALOGUE FOR THE PREPARATION OF AMINOTHIAZOLES
US4451471A (en) 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (en) 1981-08-17 1983-02-18 Rhone Poulenc Sante NEW DERIVATIVES OF CEPHALOSPORINE, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM
DE3630732A1 (en) 1986-09-10 1988-03-17 Bayer Ag 2-CYANO-2-ALKOXIMINO ACETAMIDE
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (en) 1987-09-14 1995-06-07 久光製薬株式会社 Anti-inflammatory agent consisting of substituted diphenylthiazole derivative
FR2636628B1 (en) 1988-08-25 1990-12-28 Sanofi Sa THIADIAZOLE-1,3,4 DERIVATIVES, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US5302608A (en) 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
US5856347A (en) 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
FR2735777B1 (en) 1995-06-21 1997-09-12 Sanofi Sa 4-PHENYLAMINOTHIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1150565A1 (en) 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
AU6471300A (en) 1999-08-06 2001-03-05 Takeda Chemical Industries Ltd. P38map kinase inhibitors
JP2001114690A (en) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd p38MAP KINASE INHIBITOR
AU2001244618A1 (en) 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
US7074934B2 (en) 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (en) 2000-07-31 2002-06-25 IMIDAZOL DERIVATIVES
JP4689801B2 (en) 2000-08-09 2011-05-25 ケミプロ化成株式会社 Method for producing aminothiazole derivative
JP2002053566A (en) 2000-08-11 2002-02-19 Japan Tobacco Inc Thiazole compound and pharmaceutical use thereof
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (en) 2001-02-09 2003-11-19 Telik Inc HYPERCYCLIC INHIBITORS OF THE GLICINE TRANSPORTER 2 PHARMACEUTICAL COMPOSITIONS, USE AND METHODS.
US20050080113A1 (en) 2001-06-11 2005-04-14 Shigenori Ohkawa Medicinal compositions
AR039059A1 (en) 2001-08-06 2005-02-09 Sanofi Aventis COMPOUND DERIVED FROM ACILAMINOTIAZOL, ITS USE, PROCEDURES TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND INTERMEDIARY COMPOUNDS
JP4495963B2 (en) * 2001-09-28 2010-07-07 サイクラセル リミテッド N- (4- (4-methylthiazol-5-yl) pyrimidin-2-yl) -N-phenylamines as antiproliferative compounds
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
WO2003039451A2 (en) 2001-11-08 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Thiazole pyridazinones as adenosine antagonists
CA2472763A1 (en) 2002-02-13 2003-08-21 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
AU2003210305B2 (en) 2002-02-28 2006-07-06 F. Hoffmann-La Roche Ag Thiazole derivatives as NPY receptor antagonists
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
EP1507534A4 (en) 2002-05-10 2006-11-08 Cytokinetics Inc Compounds, compositions and methods
FR2842523A1 (en) 2002-07-17 2004-01-23 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP1551815A1 (en) 2002-10-09 2005-07-13 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
CL2003002353A1 (en) 2002-11-15 2005-02-04 Vertex Pharma COMPOUNDS DERIVED FROM DIAMINOTRIAZOLS, INHIBITORS D ELA PROTEINA QUINASA; PHARMACEUTICAL COMPOSITION; PREPARATION PROCEDURE; AND ITS USE OF THE COMPOUND IN THE TREATMENT OF DISEASES OF ALLERGIC DISORDERS, PROLIFERATION, AUTOIMMUNES, CONDIC
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (en) 2003-01-23 2006-07-07 Sanofi Synthelabo ACYLAMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS
JP2006182648A (en) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7-membered heterocyclic derivative
AR044519A1 (en) 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
CA2536253A1 (en) 2003-08-20 2005-03-03 Vertex Pharmaceuticals Incorporated Aminofurazan compounds useful as protein kinase inhibitors
KR20060088537A (en) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Modulators of atp-binding cassette transporters
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
SI1709019T1 (en) 2004-01-12 2007-10-31 Serono Lab Thiazole derivatives and use thereof
WO2005073202A1 (en) 2004-01-16 2005-08-11 Sanofi-Aventis Acylaminothiazole derivatives and use thereof as beta-amyloid inhibitors
EP1709041A1 (en) 2004-01-16 2006-10-11 Sanofi-Aventis Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics
WO2005085227A1 (en) * 2004-03-02 2005-09-15 Smithkline Beecham Corporation Inhibitors of akt activity
JP4054845B2 (en) 2004-03-23 2008-03-05 ファイザー・プロダクツ・インク Imidazole compounds for the treatment of neurodegenerative disorders
CA2561977A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1740609A2 (en) * 2004-04-27 2007-01-10 Research Development Foundation Antagonism of tgf-beta superfamily receptor signaling
AU2005245962A1 (en) 2004-05-21 2005-12-01 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
CA2575466A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of atp-utilizing enzymes
SE0402735D0 (en) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
EP1854793A4 (en) 2005-02-28 2011-01-26 Japan Tobacco Inc NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY
KR101386282B1 (en) 2005-06-17 2014-04-17 아포지 바이오테크놀로지 코포레이션 Sphingosine kinase inhibitors
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (en) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazoles as fungicides
JP5064237B2 (en) 2005-12-09 2012-10-31 Meiji Seikaファルマ株式会社 Lincomycin derivatives and antibacterial agents containing the same as active ingredients
CN101331125A (en) 2005-12-12 2008-12-24 健亚生物科技公司 N-(5-membered aromatic ring)-amido anti-viral compounds
AU2007207706A1 (en) 2006-01-18 2007-07-26 Merck Sharp & Dohme Corp. Cannibinoid receptor modulators
JP2009523751A (en) 2006-01-18 2009-06-25 エフ.ホフマン−ラ ロシュ アーゲー Cis-4,5-biaryl-2-heterocyclic-imidazoline as an MDM2 inhibitor
EP1981884B1 (en) 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US20010044545A1 (en) * 2000-04-03 2001-11-22 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US20030078252A1 (en) * 2001-05-11 2003-04-24 Pfizer Inc. Thiazole derivatives
US20040122016A1 (en) * 2002-10-30 2004-06-24 Jingrong Cao Compositions useful as inhibitors of rock and other protein kinases
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006044860A2 (en) * 2004-10-18 2006-04-27 Amgen, Inc. Thiadiazole compounds and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KODOMARI M ET AL: "One-pot synthesis of 2-aminothiazoles using supported reagents", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 43, no. 9, 25 February 2002 (2002-02-25), pages 1717 - 1720, XP004340154, ISSN: 0040-4039 *
VIJAI N. PATHAK AND RAJ PAL SINGH: "Synthesis and biological properties of some new 2-(N-arylamino)-4-(fluoroaryl)thiazoles", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, vol. 56, no. 10, 1979, pages 1010 - 1012, XP009094043 *

Also Published As

Publication number Publication date
UA91895C2 (en) 2010-09-10
CN101421265A (en) 2009-04-29
NO20083572L (en) 2008-10-17
AU2007207743B2 (en) 2010-07-08
PE20071114A1 (en) 2008-01-10
TW200738657A (en) 2007-10-16
IL192751A0 (en) 2009-02-11
JP5199885B2 (en) 2013-05-15
ES2389062T3 (en) 2012-10-22
AR059064A1 (en) 2008-03-12
UY30098A1 (en) 2007-10-31
ZA200806386B (en) 2009-11-25
MY149143A (en) 2013-07-15
EP1981884B1 (en) 2012-06-13
US20070173506A1 (en) 2007-07-26
CR10211A (en) 2008-10-03
KR20080091369A (en) 2008-10-10
EP1981884A2 (en) 2008-10-22
CA2636077A1 (en) 2007-07-26
US8084479B2 (en) 2011-12-27
CA2636077C (en) 2012-01-03
US20090270445A1 (en) 2009-10-29
WO2007084391A2 (en) 2007-07-26
EA200801716A1 (en) 2009-04-28
AU2007207743A1 (en) 2007-07-26
US7514566B2 (en) 2009-04-07
BRPI0706621A2 (en) 2011-04-05
JP2009525960A (en) 2009-07-16

Similar Documents

Publication Publication Date Title
WO2007084391A3 (en) Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2009011880A3 (en) Heterocyclic modulators of pkb
WO2009011871A3 (en) Thiadiazole modulators of pkb
WO2006044860A3 (en) Thiadiazole compounds and methods of use
WO2009011850A3 (en) Novel therapeutic compounds
WO2008073933A3 (en) 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2006093547A3 (en) Novel lipoxygenase inhibitors
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2008089307A3 (en) Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
WO2005090333A8 (en) 3-‘4-heterocyclyl -1,2,3,-triazol-1-yl!-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
NO20084652L (en) Deazapurins useful as inhibitors of januskinases
EP2090577A8 (en) Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008033562A3 (en) Kinase inhibitor compounds
WO2007089335A3 (en) Multicyclic amino acid derivatives and methods of their use
WO2008074997A8 (en) Pyridine benzamides and pyrazine benzamides used as pkd inhibitors
WO2006028963A3 (en) Substituted heterocyclic compounds and uses thereof
WO2010093727A8 (en) Quinazolinones as prolyl hydroxylase inhibitors
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2007115620A3 (en) Novel cyclobutyl compounds as kinase inhibitors
MX2011006006A (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders.
WO2008054698A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2007125331A3 (en) Amino-ethyl-amino-aryl (aeaa) compounds and their use
MX2009010127A (en) N-heterocyclic compounds useful as inhibitors of janus kinases.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2636077

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008071135

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 12008501616

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 569706

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 192751

Country of ref document: IL

Ref document number: 2007207743

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/009048

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007718125

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008551297

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3974/CHENP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007207743

Country of ref document: AU

Date of ref document: 20070111

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087019941

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: CR2008-010211

Country of ref document: CR

Ref document number: 200801716

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200780009708.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: PI0706621

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080718